terfenadine has been researched along with Itching in 45 studies
Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "H1-antihistamines are the first-line treatment of chronic idiopathic urticaria (CIU), but CIU is occasionally refractory to the conventional treatment doses." | 9.17 | Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. ( Kabashima, K; Miyachi, Y; Nakahigashi, K; Tanizaki, H, 2013) |
| "Fexofenadine (n = 201) significantly decreased the severity of pruritus compared with placebo (n = 199) (mean change in score -0." | 9.10 | Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. ( Harada, S; Inagi, M; Kawashima, M; Nakagawa, H; Noguchi, T; Tango, T, 2003) |
| "In this 4-week, multicenter, placebo-controlled study, 439 patients with moderate to severe pruritus and urticaria received 1 of 4 oral doses of fexofenadine HCl (20, 60, 120, or 240 mg twice a day) or placebo." | 9.09 | A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. ( Finn, AF; Fretwell, R; Kaplan, AP; Long, J; Qu, R, 1999) |
| "We report the results of a double-blind, placebo-controlled, cross-over study of terfenadine 120 mg twice daily for pruritus in atopic dermatitis." | 9.06 | Failure of terfenadine in relieving the pruritus of atopic dermatitis. ( Berth-Jones, J; Graham-Brown, RA, 1989) |
| "45 patients with chronic urticaria were randomized to double blind therapy with terfenadine an H1-antihistamine or ranitidine, an H2-antihistamine, or a combination of both drugs." | 9.06 | Treatment of chronic urticaria with terfenadine and ranitidine. A randomized double-blind study in 45 patients. ( Bödeker, RH; Paul, E, 1986) |
| "The use of the nonsedating antihistamine terfenadine (60 mg twice daily) in the treatment of chronic idiopathic urticaria and contact urticaria associated with atopic dermatitis was assessed." | 9.06 | Terfenadine in the treatment of chronic idiopathic urticaria and atopic dermatitis. ( Hjorth, N, 1988) |
| " In this study, we investigated the anti-pruritic effect of the antihistamine, fexofenadine, on the itch of contact dermatitis that was induced by topical application of diphenylcyclopropenone for the treatment for alopecia areata." | 7.73 | Fexofenadine, an H1-receptor antagonist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcyclopropenone in patients with alopecia areata. ( Arakawa, S; Fujiwara, S; Hatano, Y; Katagiri, K, 2006) |
| "H1-antihistamines are the first-line treatment of chronic idiopathic urticaria (CIU), but CIU is occasionally refractory to the conventional treatment doses." | 5.17 | Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations. ( Kabashima, K; Miyachi, Y; Nakahigashi, K; Tanizaki, H, 2013) |
| "Fexofenadine (n = 201) significantly decreased the severity of pruritus compared with placebo (n = 199) (mean change in score -0." | 5.10 | Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. ( Harada, S; Inagi, M; Kawashima, M; Nakagawa, H; Noguchi, T; Tango, T, 2003) |
| "In this 4-week, multicenter, placebo-controlled study, 439 patients with moderate to severe pruritus and urticaria received 1 of 4 oral doses of fexofenadine HCl (20, 60, 120, or 240 mg twice a day) or placebo." | 5.09 | A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. ( Finn, AF; Fretwell, R; Kaplan, AP; Long, J; Qu, R, 1999) |
| "Pretreatment with fexofenadine during venom immunotherapy reduces local allergic reactions and generalized symptoms of the urticaria and angioedema type." | 5.09 | Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. ( Hari, Y; Müller, U; Reimers, A, 2000) |
| "We report the results of a double-blind, placebo-controlled, cross-over study of terfenadine 120 mg twice daily for pruritus in atopic dermatitis." | 5.06 | Failure of terfenadine in relieving the pruritus of atopic dermatitis. ( Berth-Jones, J; Graham-Brown, RA, 1989) |
| "45 patients with chronic urticaria were randomized to double blind therapy with terfenadine an H1-antihistamine or ranitidine, an H2-antihistamine, or a combination of both drugs." | 5.06 | Treatment of chronic urticaria with terfenadine and ranitidine. A randomized double-blind study in 45 patients. ( Bödeker, RH; Paul, E, 1986) |
| "The use of the nonsedating antihistamine terfenadine (60 mg twice daily) in the treatment of chronic idiopathic urticaria and contact urticaria associated with atopic dermatitis was assessed." | 5.06 | Terfenadine in the treatment of chronic idiopathic urticaria and atopic dermatitis. ( Hjorth, N, 1988) |
| " However, fexofenadine probably leads to a small improvement in patient-assessed pruritus, with probably no significant difference in the amount of treatment used to prevent eczema flares." | 5.01 | Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema. ( Apfelbacher, CJ; Böhmer, MM; Carter, B; Jupiter, A; Matterne, U; Weisshaar, E, 2019) |
| "Urticaria is mainly caused by mast cell-derived histamine through the histamine H(1) receptor." | 3.78 | Effects of bepotastine and fexofenadine on histamine-induced flare, wheal and itch. ( Fukuoka, M; Ikoma, A; Kabashima, K; Miyachi, Y; Tanizaki, H, 2012) |
| " In this study, we investigated the anti-pruritic effect of the antihistamine, fexofenadine, on the itch of contact dermatitis that was induced by topical application of diphenylcyclopropenone for the treatment for alopecia areata." | 3.73 | Fexofenadine, an H1-receptor antagonist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcyclopropenone in patients with alopecia areata. ( Arakawa, S; Fujiwara, S; Hatano, Y; Katagiri, K, 2006) |
| "Levocetirizine was more inhibitory than fexofenadine on wheal, flare and pruritus (p < 0." | 2.78 | The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers. ( Church, MK; Maurer, M; Schoepke, N, 2013) |
| "Fexofenadine (180 mg/d) was taken during the run-in period and subsequently throughout the study and follow-up as required." | 2.73 | Narrowband ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism: a pilot study. ( Borzova, E; Grattan, CE; Konstantinou, GN; Leslie, KS; Rutherford, A, 2008) |
| "Treatment with fexofenadine resulted in inhibition of allergen-induced symptoms and increased vascular permeability, but not the release of histamine and tryptase." | 2.70 | Effects of fexofenadine on the early response to nasal allergen challenge. ( Allocco, FT; Baroody, FM; deTineo, M; Naclerio, RM; Votypka, V, 2002) |
| " The itch responses provoked by wool fibres were significantly stronger in AD patients than in controls, whereas the histamine-induced dose-response curves for itch did not differ significantly between the two groups, who discriminated equally well between weak and strong histamine stimuli." | 2.67 | Itch and atopic dermatitis: clinical and experimental studies. ( Wahlgren, CF, 1991) |
| "The flurbiprofen-treated patients experienced less severe symptoms, demonstrating maximum benefit 3 to 5 days into the drug trial with some loss of effect thereafter." | 2.66 | Hay fever treatment with combined antihistamine and cyclooxygenase-inhibiting drugs. ( Brooks, CD; Karl, KJ, 1988) |
| " The dose-response curve of tryptase action was bell-shaped and the effect peaked at 0." | 1.33 | Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. ( Andoh, T; Kuraishi, Y; Lee, JB; Nojima, H; Ui, H, 2006) |
| " Pretreatment with antihistamines diminishes the incidence of adverse reactions (AR) such as large local and mild systemic reactions but it is suggested that it may mask a development of serious allergic reactions." | 1.33 | [Safety of venom immunotherapy in patients pretreated with antihistamines--a retrospective study]. ( Bocheńska-Marciniak, M; Kuna, P; Kupczyk, M; Kupryś-Lipińska, I; Tworek, D, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (20.00) | 18.7374 |
| 1990's | 10 (22.22) | 18.2507 |
| 2000's | 18 (40.00) | 29.6817 |
| 2010's | 8 (17.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Matterne, U | 1 |
| Böhmer, MM | 1 |
| Weisshaar, E | 1 |
| Jupiter, A | 1 |
| Carter, B | 1 |
| Apfelbacher, CJ | 1 |
| Tanizaki, H | 2 |
| Nakahigashi, K | 1 |
| Miyachi, Y | 2 |
| Kabashima, K | 2 |
| Hashimoto, T | 1 |
| Satoh, T | 1 |
| Borzova, E | 1 |
| Rutherford, A | 1 |
| Konstantinou, GN | 1 |
| Leslie, KS | 1 |
| Grattan, CE | 1 |
| Tsujii, K | 1 |
| Andoh, T | 6 |
| Lee, JB | 2 |
| Kuraishi, Y | 6 |
| Saito, A | 1 |
| Zhang, Q | 1 |
| Yamamoto, T | 1 |
| Tayama, M | 1 |
| Hattori, M | 1 |
| Tanaka, K | 1 |
| Kamei, H | 1 |
| Isaji, A | 1 |
| Noda, Y | 1 |
| Ishikawa, K | 1 |
| Senzaki, K | 1 |
| Yamada, K | 1 |
| Sugiura, K | 1 |
| Tomita, Y | 1 |
| Nabeshima, T | 1 |
| Ikoma, A | 1 |
| Fukuoka, M | 1 |
| Schoepke, N | 1 |
| Church, MK | 1 |
| Maurer, M | 1 |
| Scherer, CR | 1 |
| Lerche, C | 1 |
| Decher, N | 1 |
| Dennis, AT | 1 |
| Maier, P | 1 |
| Ficker, E | 1 |
| Busch, AE | 1 |
| Wollnik, B | 1 |
| Steinmeyer, K | 1 |
| Allocco, FT | 1 |
| Votypka, V | 1 |
| deTineo, M | 1 |
| Naclerio, RM | 1 |
| Baroody, FM | 1 |
| Kawashima, M | 1 |
| Tango, T | 1 |
| Noguchi, T | 1 |
| Inagi, M | 1 |
| Nakagawa, H | 1 |
| Harada, S | 1 |
| Yageta, Y | 1 |
| Takeshima, H | 1 |
| Lennox, RD | 2 |
| Leahy, MJ | 1 |
| Shikiar, R | 1 |
| Harding, G | 1 |
| Leahy, M | 1 |
| Ui, H | 1 |
| Nojima, H | 2 |
| Katagiri, K | 1 |
| Arakawa, S | 1 |
| Hatano, Y | 1 |
| Fujiwara, S | 1 |
| Tworek, D | 1 |
| Bocheńska-Marciniak, M | 1 |
| Kupczyk, M | 1 |
| Kupryś-Lipińska, I | 1 |
| Kuna, P | 1 |
| Yamashita, H | 1 |
| Makino, T | 1 |
| Mizukami, H | 1 |
| Nose, M | 1 |
| Ohtsuka, E | 1 |
| Nakano, T | 1 |
| Kawai, S | 1 |
| Kamimura, K | 1 |
| Benhamou, AH | 1 |
| Vanini, G | 1 |
| Lantin, JP | 1 |
| Eigenmann, PA | 1 |
| Krause, L | 1 |
| Shuster, S | 2 |
| Duncan, JS | 1 |
| Kennedy, HJ | 1 |
| Triger, DR | 1 |
| Leynadier, F | 1 |
| Murrieta, M | 1 |
| Dry, J | 1 |
| Colin, JN | 1 |
| Gillotin, C | 1 |
| Steru, D | 1 |
| Scott, DW | 1 |
| Miller, WH | 1 |
| Cayatte, SM | 1 |
| Decker, GA | 1 |
| Yee, KC | 1 |
| Cunliffe, WJ | 1 |
| Day, JH | 1 |
| Briscoe, MP | 1 |
| Clark, RH | 1 |
| Ellis, AK | 1 |
| Gervais, P | 1 |
| Brockow, K | 1 |
| Kiehn, M | 1 |
| Riethmüller, C | 1 |
| Vieluf, D | 1 |
| Berger, J | 1 |
| Ring, J | 1 |
| Finn, AF | 1 |
| Kaplan, AP | 1 |
| Fretwell, R | 1 |
| Qu, R | 1 |
| Long, J | 1 |
| Phillips, RL | 1 |
| Koenig, CJ | 1 |
| Reimers, A | 1 |
| Hari, Y | 1 |
| Müller, U | 1 |
| Takizawa, T | 1 |
| Matsumoto, J | 1 |
| Tohma, T | 1 |
| Kanke, T | 1 |
| Wada, Y | 1 |
| Nagao, M | 1 |
| Inagaki, N | 1 |
| Nagai, H | 1 |
| Zhang, MQ | 1 |
| Timmerman, H | 1 |
| Abu Shareeah, AM | 1 |
| Duffull, SB | 1 |
| Begg, EJ | 1 |
| Wahlgren, CF | 2 |
| Hägermark, O | 1 |
| Bergström, R | 1 |
| Doherty, V | 1 |
| Sylvester, DG | 1 |
| Kennedy, CT | 1 |
| Harvey, SG | 1 |
| Calthrop, JG | 1 |
| Gibson, JR | 1 |
| Cox, NH | 1 |
| Higgins, EM | 1 |
| Forr, PM | 1 |
| Berth-Jones, J | 1 |
| Graham-Brown, RA | 1 |
| Paul, E | 1 |
| Bödeker, RH | 1 |
| Brooks, CD | 1 |
| Karl, KJ | 1 |
| Hjorth, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Efficacy and Consistency of Action of Levocetirizine 5 mg Once Daily With Fexofenadine 60 mg Twice Daily in the Histamine Induced Wheal, Flare and Itch Response[NCT01586091] | Phase 4 | 18 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Flaire diameter was measured with a transparent ruler as the mean of the largest diameter and the diameter at right angles to this. (NCT01586091)
Timeframe: 24 hours per treatment
| Intervention | mm (Mean) |
|---|---|
| Placebo | 69.4 |
| Levocetirizin | 20.4 |
| Fexofenadine | 39.9 |
"We measured drug concentrations and various aspects of skin provocation testing such as itch intensity and wheal size. Measurements made at each time point were as followed: Pruritus was assessed every 30 s for 10 min after SPT using a visual analogue scale (VAS) score with a 0 and 100 at the two ex- tremes of an unmarked 100 mm line with higher values indicating greater puritus. The mean VAS for each 10 min was calculated and used as a primary end Point." (NCT01586091)
Timeframe: up to 10 minutes after skin prick test performed 24 hours after drug administration
| Intervention | mm (Mean) |
|---|---|
| Levocetirizin | 11.5 |
| Fexofenadine | 25.4 |
| Placebo | 46.0 |
Wheal volume was measured by a non-contact three dimensional measurement system (PRIMOS contact, GFM Messtechnik GmbH, Teltow, Germany). (NCT01586091)
Timeframe: 24 hours per treatment
| Intervention | cm3 (Mean) |
|---|---|
| Placebo | 174.6 |
| Levocetirizin | 35.2 |
| Fexofenadine | 106.3 |
1 review available for terfenadine and Itching
| Article | Year |
|---|---|
Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema.
Topics: Administration, Oral; Administration, Topical; Adult; Cetirizine; Chemotherapy, Adjuvant; Child; Ecz | 2019 |
24 trials available for terfenadine and Itching
| Article | Year |
|---|---|
Comparison of the efficacy of fexofenadine 120 and 240 mg/day on chronic idiopathic urticaria and histamine-induced skin responses in Japanese populations.
Topics: Adult; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Histamine; Histamine H1 Ant | 2013 |
Narrowband ultraviolet B phototherapy is beneficial in antihistamine-resistant symptomatic dermographism: a pilot study.
Topics: Adult; Drug Resistance; Female; Histamine H1 Antagonists; Humans; Male; Pilot Projects; Prospective | 2008 |
Effects of single therapeutic doses of promethazine, fexofenadine and olopatadine on psychomotor function and histamine-induced wheal- and flare-responses: a randomized double-blind, placebo-controlled study in healthy volunteers.
Topics: Adolescent; Dibenzoxepins; Double-Blind Method; Female; Histamine H1 Antagonists; Humans; Male; Olop | 2012 |
The inhibition by levocetirizine and fexofenadine of the histamine-induced wheal and flare response in healthy Caucasian and Japanese volunteers.
Topics: Adult; Asian People; Cetirizine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind | 2013 |
Effects of fexofenadine on the early response to nasal allergen challenge.
Topics: Adolescent; Adult; Allergens; Biomarkers; Capillary Permeability; Cross-Over Studies; Double-Blind M | 2002 |
Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Dermatitis, Atopic; Dermatologic Agents; Double-Blind | 2003 |
Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life.
Topics: Chronic Disease; Dermatology; Dose-Response Relationship, Drug; Double-Blind Method; Histamine H1 An | 2004 |
Mechanism of action of antipruritic drugs.
Topics: Adolescent; Adult; Aged; Antipruritics; Astemizole; Benzhydryl Compounds; Benzimidazoles; Female; Hi | 1983 |
Treatment of pruritus due to chronic obstructive liver disease.
Topics: Benzhydryl Compounds; Chlorpheniramine; Cholangitis; Cholestyramine Resin; Clinical Trials as Topic; | 1984 |
Effects of acrivastine and terfenadine on skin reactivity to histamine.
Topics: Drug Hypersensitivity; Histamine; Histamine H1 Antagonists; Humans; Pruritus; Skin; Skin Tests; Terf | 1994 |
Failure of terfenadine as an antipruritic agent in atopic dogs: results of a double-blinded, placebo-controlled study.
Topics: Administration, Oral; Animals; Dog Diseases; Dogs; Double-Blind Method; Female; Hypersensitivity, Im | 1994 |
Onset of action and efficacy of terfenadine, astemizole, cetirizine, and loratadine for the relief of symptoms of allergic rhinitis.
Topics: Adolescent; Adult; Anti-Allergic Agents; Astemizole; Cetirizine; Double-Blind Method; Environmental | 1997 |
Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Animals; Arthropod Venoms; Desensitization, Immunolog | 1997 |
A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Child; Chronic Disease; Double-Blind Method; Female; Histamine H1 Antagonis | 1999 |
Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Angioedema; Anti-Allergic Agents; Bee Venoms; Double-Blind Method; Drug Therapy, | 2000 |
Comparative efficacy of loratadine and terfenadine in the treatment of chronic idiopathic urticaria.
Topics: Adult; Chronic Disease; Cyproheptadine; Female; Histamine Antagonists; Humans; Loratadine; Male; Pru | 1992 |
Terfenadine ineffective in the prophylaxis of exercise-induced pruritus.
Topics: Adult; Exercise; Humans; Male; Pruritus; Running; Terfenadine; Urticaria | 1992 |
Itch and atopic dermatitis: clinical and experimental studies.
Topics: Adolescent; Adult; Clemastine; Cyclosporine; Dermatitis, Atopic; Double-Blind Method; Female; Histam | 1991 |
The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis.
Topics: Adolescent; Adult; Benzhydryl Compounds; Clemastine; Dermatitis, Atopic; Double-Blind Method; Female | 1990 |
Treatment of itching in atopic eczema with antihistamines with a low sedative profile.
Topics: Adolescent; Adult; Benzhydryl Compounds; Clinical Trials as Topic; Dermatitis, Atopic; Female; Hista | 1989 |
Failure of terfenadine in relieving the pruritus of atopic dermatitis.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Child; Dermatitis, Atopic; Double-Blind Method; Hista | 1989 |
Treatment of chronic urticaria with terfenadine and ranitidine. A randomized double-blind study in 45 patients.
Topics: Adult; Aged; Benzhydryl Compounds; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; | 1986 |
Hay fever treatment with combined antihistamine and cyclooxygenase-inhibiting drugs.
Topics: Adult; Benzhydryl Compounds; Conjunctivitis; Cyclooxygenase Inhibitors; Drug Therapy, Combination; F | 1988 |
Terfenadine in the treatment of chronic idiopathic urticaria and atopic dermatitis.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Chronic Disease; Clemastine; Dermatitis, Atopic; Doub | 1988 |
20 other studies available for terfenadine and Itching
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Generalized pruritus in primary sclerosing cholangitis: implications of histamine release by lysophosphatidic acid.
Topics: Adolescent; Cholangitis, Sclerosing; Histamine H1 Antagonists, Non-Sedating; Histamine Release; Huma | 2015 |
Activation of proteinase-activated receptors induces itch-associated response through histamine-dependent and -independent pathways in mice.
Topics: Animals; Behavior, Animal; Dose-Response Relationship, Drug; Histamine; Histamine H1 Antagonists, No | 2008 |
Leukotriene B(4) mediates sphingosylphosphorylcholine-induced itch-associated responses in mouse skin.
Topics: Animals; Calcium; Dermatitis, Atopic; Ganglia, Spinal; Histamine; Histamine H1 Antagonists, Non-Seda | 2009 |
Inhibitory effects of the methanol extract of Ganoderma lucidum on mosquito allergy-induced itch-associated responses in mice.
Topics: Animals; Antipruritics; Culicidae; Drugs, Chinese Herbal; Fruit; Histamine; Histamine H1 Antagonists | 2010 |
Effects of bepotastine and fexofenadine on histamine-induced flare, wheal and itch.
Topics: Adult; Female; Histamine; Histamine H1 Antagonists, Non-Sedating; Humans; Male; Piperidines; Pruritu | 2012 |
The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia.
Topics: Aged; Amino Acid Sequence; Amino Acid Substitution; Animals; Arrhythmias, Cardiac; Base Sequence; Bl | 2002 |
Intradermal nociceptin elicits itch-associated responses through leukotriene B(4) in mice.
Topics: Animals; Anti-Allergic Agents; Dermatitis; Immunosuppressive Agents; Injections, Intradermal; Kerati | 2004 |
Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria.
Topics: Adolescent; Adult; Aged; Child; Chronic Disease; Clinical Trials, Phase III as Topic; Data Interpret | 2005 |
Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice.
Topics: Animals; Antibodies; Antipruritics; Benzamidines; Dose-Response Relationship, Drug; Extravasation of | 2006 |
Fexofenadine, an H1-receptor antagonist, partially but rapidly inhibits the itch of contact dermatitis induced by diphenylcyclopropenone in patients with alopecia areata.
Topics: Adolescent; Adult; Aged; Alopecia Areata; Cohort Studies; Cyclopropanes; Dermatitis, Contact; Dose-R | 2006 |
[Safety of venom immunotherapy in patients pretreated with antihistamines--a retrospective study].
Topics: Adolescent; Adult; Aged; Anaphylaxis; Animals; Bee Venoms; Desensitization, Immunologic; Erythema; F | 2006 |
Pharmacological characterization of a chronic pruritus model induced by multiple application of 2,4,6-trinitrochlorobenzene in NC mice.
Topics: Animals; Antipruritics; Cell Degranulation; Chronic Disease; Cromolyn Sodium; Cyproheptadine; Dermat | 2007 |
Possible involvement of 5-lipoxygenase metabolite in itch-associated response of mosquito allergy in mice.
Topics: Animals; Arachidonate 5-Lipoxygenase; Betamethasone Valerate; Bridged Bicyclo Compounds, Heterocycli | 2007 |
Antihistamine and sodium cromoglycate medication for food cold water exercise-induced anaphylaxis.
Topics: Adolescent; Anaphylaxis; Anti-Asthmatic Agents; Cold Temperature; Cromolyn Sodium; Drug Therapy, Com | 2007 |
Itching in acne--an unusual complication of therapy.
Topics: Acne Vulgaris; Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Anti-Bacterial Ag | 1994 |
Antihistamines for atopic dermatitis.
Topics: Adolescent; Adult; Aged; Antipruritics; Cetirizine; Child; Clemastine; Dermatitis, Atopic; Double-Bl | 2000 |
VUF-K-8788, a periphery-selective histamine H1 antagonist with anti-pruritic activities.
Topics: Animals; Anti-Allergic Agents; Behavior, Animal; Benzimidazoles; Capillary Permeability; Guinea Pigs | 2001 |
Terfenadine inhibits itch and wheal, but not abnormal erythema, in physical urticarias.
Topics: Adult; Benzhydryl Compounds; Erythema; Female; Histamine H1 Antagonists; Humans; Middle Aged; Prurit | 1989 |
Antihistamines in the treatment of urticarial disorders.
Topics: Astemizole; Benzhydryl Compounds; Benzimidazoles; Chronic Disease; Histamine H1 Antagonists; Humans; | 1988 |